- Home
- RVYL vs KZIA Comparison
RVYL vs KZIA Comparison
Compare RVYL & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVYL
- KZIA
- Stock Information
- Founded
- RVYL 2007
- KZIA 1994
- Country
- RVYL United States
- KZIA Australia
- Employees
- RVYL N/A
- KZIA N/A
- Industry
- RVYL Professional Services
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- RVYL Consumer Discretionary
- KZIA Health Care
- Exchange
- RVYL Nasdaq
- KZIA Nasdaq
- Market Cap
- RVYL 5.4M
- KZIA 5.1M
- IPO Year
- RVYL N/A
- KZIA 1999
- Fundamental
- Price
- RVYL $0.85
- KZIA $6.10
- Analyst Decision
- RVYL Hold
- KZIA Strong Buy
- Analyst Count
- RVYL 1
- KZIA 2
- Target Price
- RVYL N/A
- KZIA $57.50
- AVG Volume (30 Days)
- RVYL 34.6M
- KZIA 2.6M
- Earning Date
- RVYL 08-12-2025
- KZIA 07-07-2025
- Dividend Yield
- RVYL N/A
- KZIA N/A
- EPS Growth
- RVYL N/A
- KZIA N/A
- EPS
- RVYL N/A
- KZIA N/A
- Revenue
- RVYL $54,357,000.00
- KZIA $1,549,158.00
- Revenue This Year
- RVYL $27.50
- KZIA N/A
- Revenue Next Year
- RVYL $35.71
- KZIA N/A
- P/E Ratio
- RVYL N/A
- KZIA N/A
- Revenue Growth
- RVYL N/A
- KZIA 248983.08
- 52 Week Low
- RVYL $0.36
- KZIA $2.86
- 52 Week High
- RVYL $2.40
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- RVYL 52.78
- KZIA 50.96
- Support Level
- RVYL $0.60
- KZIA $5.83
- Resistance Level
- RVYL $0.91
- KZIA $9.60
- Average True Range (ATR)
- RVYL 0.10
- KZIA 1.19
- MACD
- RVYL 0.02
- KZIA -0.29
- Stochastic Oscillator
- RVYL 57.41
- KZIA 18.39
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.